UBS has initiated coverage on Blink Charging Co. (Nasdaq: BLNK), a leading provider of electric vehicle charging services, with a Buy rating and a price target of $7.

With $BLNK closing at $2.93 on Tuesday, the price target suggests a significant potential upside of $4.07 or 138.85%, according to the investment services firm's evaluation.

In other news, Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) has unveiled a significant collaboration with Pfizer Inc. (NYSE: PFE), with a primary focus on pioneering RNA-based drug candidates. This partnership will see Pfizer harnessing Ginkgo's cutting-edge RNA technology to advance the discovery and development of innovative RNA molecules, particularly within key research domains.

As part of the deal, Ginkgo will receive an initial payment and stands to earn research fees, development milestones, and potential commercial payments, potentially amounting to a substantial $331 million across three distinct programs. Furthermore, Ginkgo may also realize downstream value through royalties based on sales.

$DNA was trading at $1.99 in pre-market, up $0.26 (+15.02%)

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)